.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Dissecting Pivotal Research in Lower-Risk MDS From ASCO 2025

Guillermo Garcia-Manero, MD, details key updates in lower-risk myelodysplastic syndrome around the 2025 ASCO Annual Meeting.

EP. 1: Recent Shifts in the Management of Lower-Risk MDS

June 19th 2025

Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.

EP. 2: OS Data From COMMANDS for Luspatercept in ESA-Naive, Lower-Risk MDS

June 26th 2025

Guillermo Garcia-Manero, MD, discusses OS data from the COMMANDS trial for luspatercept in ESA-naive, lower-risk MDS.

EP. 3: How Data Are Defining the Role of Luspatercept in ESA-Naive, Lower-Risk MDS

July 10th 2025

Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.